Genmab's total assets for Q2 2026 were kr12.52B, an increase of 1.12% from the previous quarter. DE:GE91 total liabilities were kr6.56B for the fiscal quarter, a -2.03% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.